NCI MAMMOGRAPHY SCREENING RECOMMENDATIONS SHOULD BE REVISED
This article was originally published in The Gray Sheet
Executive Summary
NCI MAMMOGRAPHY SCREENING RECOMMENDATIONS SHOULD BE REVISED to reflect the possibility of benefit from screening women under age 50, the House Committee on Government Operations asserts in a report approved Oct. 7 by the committee. The report, entitled "Misused Science: The National Cancer Institute's Elimination of Mammography Guidelines for Women in their Forties," criticizes NCI's decision to eliminate screening guidelines for women aged 40-49 and maintains that NCI has "created confusion about the importance of mammography screening."
You may also be interested in...
As Casgevy, Lyfgenia Launches Proceed, CRISPR And bluebird bio CEOs Reassure
The CEOs of bluebird bio and CRISPR Therapeutics hope to inspire investor confidence that their gene-based therapies for sickle cell disease and beta thalassemia will be widely reimbursed in the US and EU.
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.